Anuh Pharma Ltd

Anuh Pharma Ltd Technicals

Anuh Pharma Ltd Financials

Anuh Pharma Ltd Shareholding Pattern

About Anuh Pharma Ltd

Anuh Pharma Limited is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The Company is engaged in the business of manufacturing and selling of Bulk drugs and chemicals. The company is part of the SK Group with the key products including Antibiotics, Erythromycin Salts, Chloramphenicol and Other Chemicals. It positions to service the existing and potential markets through manufacturing unit at Tarapur, Maharashtra. The Company was incorporated on February 19, 1960. The company is well positioned to service their existing and potential markets through their manufacturing operations at Tarapur in Maharashtra. All the facilities are built and operated according to cGMP. They also received plant approvals from several MNCs. The business headquarters of the firm is located in the commercial capital of India, Mumbai. The company is a recognized export house and exports their products to Mexico, Brazil, Iran, Bangladesh, Colombia, Germany, Africa, Singapore and several other countries. During the year 2006-07, the company commissioned the new plant with all latest modern techniques and facilities. Thus, the production capacity of Antibiotics increased from 400,000 Kg to 600,000 Kg. During the year 2008-09, the company completed the on-going expansion of their plant, thus they increased the installed capacity by 150 MT per annum. In September 2008, they expanded unit started commercial production. In January 2010, the company received approv ...al for their product Erythromycin E.P. from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Erythromycin E.P. in European counties for their own consumption. In April 2010, the company received approval for their product Pyrazinamide from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Pyrazinamide in European countries for their own consumption. In June 2010, the company received approval for their product Clobetasol Propionate from European Directorate for the Quality Medicines & Healthcare. This approval paves the way for the company to sell Clobetasol Propionate in European counties for their own consumption. The erection of a new plant for manufacture of drug intermediates, was completed during the year 2010-11 and it got commissioned towards end of February, 2011. In 2012, it received WHO - PQ for Pyrazinamide & acquired R&D assets in Mahape, Navi Mumbai & got DSIR approval. In 2014, it got approval from COFEPRIS - Mexico for Erythromycin Estolate, Erythromycin Stearate, Erythromycin Ethyl Succinate. In 2015, it received approval of WHO - PQ for Sulfadoxine. In March 2019, the Company opened new expansion with an additional capacity of 900 MTPA for 20 different products. It commissioned the new expansion project by starting commercial production in December, 2019. It received CEP for Ambroxol Hydrochloride from EDQM in 2022. In FY 2023-24, Company enhanced production capacity from 1,500 MTPA to 1,800 MTPA at Boisar site. In FY 2025, Company launched 6 new products, adding 40 new export customers and partnerships, and further enhancing the regulatory foundation. During 2025-26, Company has inaugurated its new Manufacturing Block INT-1A situated at MIDC, Tarapur, in Palghar District on 15 July, 2025, which enhanced existing overall manufacturing capacity by 200 MT/Annum. Further, Company enhanced the existing capacity from 2,200 MTPA to 2,400 MTPA at the Boisar site, including the installation of 40 KL of reactor capacity being added during the year

Similar Stocks